Astex
Pharmaceuticals ASTX, a pharmaceutical company dedicated to the
discovery and development of novel small molecule therapeutics, Cancer
Research Technology Limited (CRT) and Newcastle University have signed a major
five-year strategic drug discovery alliance. The partners will discover and
develop new cancer drugs in collaboration with researchers at the Cancer
Research UK Drug Discovery Program at the Northern Institute for Cancer
Research (NICR, Newcastle University).
During the five-year alliance, Astex will provide £1M funding annually to
Newcastle University to support research across biology, chemistry,
pharmacology and imaging at the NICR to identify and develop new cancer drugs
and associated biomarkers to develop tests to determine which patients to
treat and if new drugs are working.
Harren Jhoti, PhD, president and director of Astex Pharmaceuticals, said, "We
are delighted to enter into this broad strategic drug discovery alliance with
one of Cancer Research UK's leading drug discovery centers as it allows Astex
to access world-leading translational research in oncology."
"This new alliance builds on a previous collaboration between Astex, Newcastle
and CRT on FGFr, a key cancer target, which led to the development of a
clinical candidate that our partners at Janssen have recently taken into a
Phase I clinical trial, and we look forward to discovering more new potential
therapies for cancer patients."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in